NCT04621916View on ClinicalTrials.gov

Preventing Inhibitor Recurrence Indefinitely

PHASE4Active, not recruitingINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

September 21, 2020

Primary Completion Date

September 20, 2024

Study Completion Date

April 20, 2025

Conditions
Hemophilia AImmune Tolerance
Interventions
DRUG

FVIII

This study will evaluate the inhibitor recurrence with or without ongoing FVIII exposure in patients with hemophilia A on emicizumab prophylaxis after a successful immune tolerance induction.

DRUG

Emicizumab

This study will evaluate the inhibitor recurrence with or without ongoing FVIII exposure in patients with hemophilia A on emicizumab prophylaxis after a successful immune tolerance induction.

Trial Locations (1)

90027

Childrens Hospital Los Angeles, Los Angeles

All Listed Sponsors
collaborator

Grifols Biologicals, LLC

INDUSTRY

lead

Children's Hospital Los Angeles

OTHER